Targeting Macrophage-Associated Core Genes for Prognostic Prediction and Therapeutic Insights in Bladder Cancer

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Bladder cancer (Bca) is a highly malignant tumor characterized by a high recurrence and metastasis rate. Macrophages crucially affect tumor progression and immunotherapy response, while researches have not well explored their precise mechanisms of action against Bca. The study aims at investigating the function of macrophage-related genes (MRGs) within the Bca immune microenvironment and exploring their potential value in prognosis prediction and therapeutic decision-making. Method: This study integrated Bca transcriptomic data from the TCGA and GEO databases along with single-cell RNA sequencing (scRNA-seq) data to systematically identify key MRGs. Differential expression analysis, weighted gene co-expression network analysis (WGCNA), and single-cell sequencing analysis served for screening for core MRGs. The results from LASSO Cox regression analysis were used for constructing a survival risk prediction model, together with the evaluation of the model’s predictive accuracy. Besides, core MRGs were subjected to immune cell infiltration and drug sensitivity analyses for the elucidation of their roles in immune regulation and therapeutic response. Furthermore, key genes in the prognostic model were validated using PCR, Western blot, and immunohistochemistry. Result: This study identified 11 core genes significantly associated with macrophages and developed a risk prediction model based on ANXA1, ST3GAL5, and VIM. The model demonstrated high predictive accuracy across all samples (AUC = 0.682). Immune analysis revealed that high-risk patients exhibited a distinctly immunosuppressive tumor microenvironment (TME), characterized by increased infiltration of M2 macrophages and neutrophils, along with a significant reduction in effector immune cells of CD8⁺ T cells and NK cells. Additionally, high-risk patients displayed greater sensitivity to targeted therapies (e.g., EGFR and HER2 inhibitors) but reduced sensitivity to conventional chemotherapy. According to in vitro and in vivo experiments, ST3GAL5 overexpression significantly promoted Bca cell proliferation and tumor growth, underscoring its potential role in tumor progression. Conclusion: This study highlights the crucial impact of MRGs on the TME of Bca and constructs a risk prediction model that effectively predicts patient survival outcomes, providing a theoretical foundation and practical guidance for personalized treatment strategies. Future researches are suggested to more deeply elucidate the functional mechanisms of these core genes as well as explore their potential as therapeutic targets for Bca.

Article activity feed